XDNA Stock Price, Chart, Stats & News
Kelly CRISPR & Gene Editing Technology ETF (XDNA) does not currently pay a dividend.
XDNA chart
Price history is unavailable
We don't have enough price data for XDNA to draw a chart yet.
XDNA returns
| YTD | -25.75% |
| 1Y | -32.72% |
| 3Y | 0.00% |
| 5Y | 0.00% |
| 10Y | 0.00% |
| 1Y volatility | 37.91% |
| 3Y volatility | 0.00% |
| Sharpe ratio | 0.00 |
About
The fund employs a passive investment strategy, aiming to replicate the total return performance of its benchmark index. This index is rule-based, comprising equities or their corresponding depositary receipts from companies involved in the entire spectrum of DNA Modification Technology, including its invention, advancement, production, operation, provision, distribution, ownership, maintenance, licensing, leasing, or franchising. A minimum of 80% of the fund's net assets are dedicated to enterprises focused on DNA Modification Technology.
Top 10 XDNA holdings
| Holding | Ownership |
|---|---|
Health care 15.10% | |
Health care 13.50% | |
Health care 9.79% | |
Health care 9.04% | |
Health care 5.93% | |
Health care 5.86% | |
Health care 4.98% | |
Health care 4.28% | |
Health care 4.19% | |
Health care 3.87% |
Similar securities
Based on sector and market capitalization
